Vitamin E (tocopherol)

Physiological Roles

• Fat-soluble membrane antioxidant (primary role) peroxyl radical ROO• neutralization in phospholipid membranes + LDLs + erythrocytes → protection of PUFAs from lipid peroxidation → maintenance of membrane integrity + prevention of hemolysis + protection of neurons (rich in PUFAs)
• Neurological function Protection of neurons and Schwann cells (myelination) against oxidative stress → deficiency leads to progressive degeneration of the spinal cord posterior funiculi + peripheral nerves + and cerebellum
• Immunity Immune response modulation + T lymphocyte proliferation stimulation + reduction of pro-inflammatory prostaglandin production
• Hematology: protection of erythrocytes from oxidative hemolysis → deficiency in premature infants leads to hemolytic anemia
• Cardiovascular effects (unconfirmed hypothesis): Observational studies suggested a protective effect of vitamin E on cardiovascular risk (prevention of LDL oxidation), but large randomized studies (HOPE, HOPE-TOO, HPS) did not demonstrate a cardiovascular benefit from vitamin E supplementation in at-risk adults.

Vitamin E Deficiency — Manifestations and At-Risk Populations

• Spinocerebellar neuropathy (main manifestation): Progressive ataxia + osteotendinous areflexia (loss of reflexes) + peripheral neuropathy (paresthesias + deep sensory disturbances) + ophthalmoplegia + retinitis pigmentosa + muscle weakness + clinically similar to Friedreich's ataxia → serum vitamin E level if unexplained progressive ataxia
• Hemolytic anemia in the premature infant: Low vitamin E red blood cells + oxidative stress → hemolysis → anemia
• Populations at risk (developed countries): Cystic fibrosis (fat-soluble malabsorption) + abetalipoproteinemia (absence of lipoprotein transport → severe deficiency from childhood) + intestinal malabsorption syndrome (Crohn's disease + extensive bariatric surgery + intestinal resection) + severe chronic cholestasis + premature infant (insufficient reserves)
• Serum dosage plasma alpha-tocopherol — normal values 12–46 µmol/L (5–20 mg/L) → deficiency if <12 µmol/L + ideally report relative to total cholesterol (alpha-tocopherol/cholesterol ratio) to correct for variations related to transport lipids

Food sources and needs

• Main sources: Wheat germ oil (richest - 149 mg/100 g) + sunflower oil (41 mg/100 g) + safflower oil + almonds + hazelnuts + peanuts + sunflower seeds + avocado + spinach + broccoli + mango
• Recommended Nutritional Intakes (Health Canada — DRI): Adult man and woman: 15 mg/day of alpha-tocopherol (22.5 IU of natural form d-alpha-tocopherol + or 33 IU of synthetic form dl-alpha-tocopherol) + pregnancy: 15 mg/day + breastfeeding: 19 mg/day
• Tolerable upper limit 1,000 mg/day (1,500 IU) of alpha-tocopherol in adults → beyond: increased hemorrhagic risk due to anti-vitamin K effect
• Units: 1 mg of natural alpha-tocopherol (d-alpha) = 1.49 IU + 1 mg of synthetic alpha-tocopherol (dl-alpha) = 1.10 IU → the natural form is 1.36 times more active than the synthetic form

Supplementation and drug interactions

• Medical supplementation indications: Documented fat-soluble malabsorption (cystic fibrosis + abetalipoproteinemia + cholestasis + Ataxia with Vitamin E Deficiency (AVED) + premature infant at risk for hemolytic anemia)
• Ataxia with Vitamin E Deficiency (AVED) Autosomal recessive disease caused by a mutation in the TTPA gene (alpha-TTP - hepatic alpha-tocopherol transfer protein) → severe deficiency despite normal dietary intake → oral supplementation at very high doses (400–1200 mg/day) → improvement or stabilization of ataxia if treated early
• Interaction with anticoagulants (VKA — warfarin): Vitamin E at doses >400 IU/day partially inhibits vitamin K-dependent carboxylase → potentiation of warfarin's anticoagulant effect → increased bleeding risk → INR may rise → inform patient + monitor INR if vitamin E supplementation is initiated or modified while on warfarin.
• Interaction with aspirin + NSAIDs: Additive antiplatelet effect at high doses → increased bleeding risk
• Preventive supplementation in the general population is not recommended: Large randomized trials (HOPE + GISSI + Alpha-Tocopherol Beta-Carotene Cancer Prevention Study) have not demonstrated a benefit in cardiovascular prevention, cancer, or dementia, indicating no indication for systematic supplementation in the general population without a documented deficiency.

Consult at Clinique Omicron

Clinique Omicron's physician assistants and nurse practitioners (PAs and NPs) measure serum vitamin E levels in populations at risk of malabsorption (cystic fibrosis, bariatric surgery, Crohn's disease, cholestasis) and in cases of unexplained progressive ataxia. They prescribe alpha-tocopherol supplementation based on the level of deficiency and etiology, warn patients on warfarin about the risk of interaction with high-dose vitamin E, and advise against preventive supplementation without a documented indication. Consultations are available at several service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.

The content of this page is for informational purposes only and does not substitute for medical or nutritional advice. Vitamin E supplementation at high doses (>400 IU/day) may potentiate the anticoagulant effect of warfarin and increase the risk of bleeding—always inform your doctor. Large randomized studies have not demonstrated cardiovascular or anti-cancer benefits from vitamin E supplementation in the general population.